Compare · ESTA vs EW
ESTA vs EW
Side-by-side comparison of Establishment Labs Holdings Inc. (ESTA) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESTA and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $52.38B, about 24.4x ESTA ($2.15B).
- ESTA has been more active in the news (5 items in the past 4 weeks vs 3 for EW).
- EW has more recent analyst coverage (25 ratings vs 14 for ESTA).
- Company
- Establishment Labs Holdings Inc.
- Edwards Lifesciences Corporation
- Price
- -
- -
- Market cap
- $2.15B
- $52.38B
- 1M return
- -21.67%
- -
- 1Y return
- +72.61%
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 5
- 3
- Recent ratings
- 14
- 25
Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ESTA
- Establishment Labs upgraded by Citigroup with a new price target
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- SEC Form 10-Q filed by Establishment Labs Holdings Inc.
- Establishment Labs Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Establishment Labs® Reports Second Quarter 2026 Financial Results
- SEC Form SCHEDULE 13G filed by Establishment Labs Holdings Inc.
- Establishment Labs® to Announce Second Quarter 2026 Financial Results on August 6
- Director Chacon Quiros Juan Jose was granted 11,315 shares, increasing direct ownership by 25% to 56,508 units (SEC Form 4)
- SEC Form 4 filed by Director Lewin Nicholas Sheridan
- Amendment: Director Harris Taylor C. was granted 3,722 shares (SEC Form 4)
Latest EW
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,967 worth of shares (619 units at $92.03) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Edwards Lifesciences Corporation
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- CVP, JAPAC Markowitz Wayne sold $12,588 worth of shares (146 units at $86.03), decreasing direct ownership by 0.67% to 21,534 units (SEC Form 4)
- CVP, JAPAC Markowitz Wayne exercised 9,628 shares at a strike of $74.02 and sold $818,958 worth of shares (9,628 units at $85.06) (SEC Form 4)
- UBS initiated coverage on Edwards Lifesciences with a new price target
- CEO Zovighian Bernard J gifted 320 shares, received a gift of 320 shares and sold $245,134 worth of shares (2,921 units at $83.93), decreasing direct ownership by 0.32% to 98,845 units (SEC Form 4)
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results